| Online-Ressource |
Verfasst von: | Borchers, Sylvia [VerfasserIn]  |
| Nowak, Yvonne [VerfasserIn]  |
| Umansky, Viktor [VerfasserIn]  |
| Utikal, Jochen [VerfasserIn]  |
Titel: | Detection of ABCB5 tumour antigen‐specific CD8+ T cells in melanoma patients and implications for immunotherapy |
Verf.angabe: | S. Borchers, C. Maβlo, C.A. Müller, A. Tahedl, J. Volkind, Y. Nowak, V. Umansky, J. Esterlechner, M.H. Frank, C. Ganss, M.A. Kluth and J. Utikal |
Jahr: | 2018 |
Jahr des Originals: | 2017 |
Umfang: | 10 S. |
Fussnoten: | Im Titel ist die Zahl "5" tief- und das Zeichen "+" hochgestellt ; First published: 23 September 2017 ; Gesehen am 02.04.2020 |
Titel Quelle: | Enthalten in: Clinical & experimental immunology |
Ort Quelle: | Oxford : Wiley-Blackwell, 1966 |
Jahr Quelle: | 2018 |
Band/Heft Quelle: | 191(2018), 1, Seite 74-83 |
ISSN Quelle: | 1365-2249 |
Abstract: | ATP binding cassette subfamily B member 5 (ABCB5) has been identified asa tumour-initiating cell marker and is expressed in various malignancies,including melanoma. Moreover, treatment with anti-ABCB5 monoclonalantibodies has been shown to inhibit tumour growth in xenotransplantationmodels. Therefore, ABCB5 represents a potential target for cancerimmunotherapy. However, cellular immune responses against ABCB5 inhumans have not been described so far. Here, we investigated whetherABCB5-reactive T cells are present in human melanoma patients and testedthe applicability of ABCB5-derived peptides for experimental induction ofhuman T cell responses. Peripheral blood mononuclear cells (PBMNC)isolated from blood samples of melanoma patients (n540) were stimulatedwith ABCB5 peptides, followed by intracellular cytokine staining (ICS) forinterferon (IFN)-gand tumour necrosis factor (TNF)-a. To evaluateimmunogenicity of ABCB5 peptides in naive healthy donors, CD8 T cellswere co-cultured with ABCB5 antigen-loaded autologous dendritic cells(DC). ABCB5 reactivity in expanded T cells was assessed similarly by ICS.ABCB5-reactive CD81T cells were detectedex vivoin 19 of 29 patients,melanoma antigen recognised by T cells (MART-1)-reactive CD81T cells insix of 21 patients. In this small, heterogeneous cohort, reactivity againstABCB5 was significantly higher than against MART-1. It occurredsignificantly more often and independently of clinical characteristics.Reactivity against ABCB5 could be induced in 14 of 16 healthy donorsinvitroby repeated stimulation with peptide-loaded autologous DC. AsABCB5-reactive CD8 T cells can be found in the peripheral blood ofmelanoma patients and an ABCB5-specific response can be inducedin vitroin naive donors, ABCB5 could be a new target for immunotherapies inmelanoma. |
DOI: | doi:10.1111/cei.13053 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/cei.13053 |
| DOI: https://doi.org/10.1111/cei.13053 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1693811014 |
Verknüpfungen: | → Zeitschrift |
Detection of ABCB5 tumour antigen‐specific CD8+ T cells in melanoma patients and implications for immunotherapy / Borchers, Sylvia [VerfasserIn]; 2018 (Online-Ressource)